Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

New Horizon Health 1H21: On Track to a Strong Year

New Horizon Health (诺辉健康) IPO Trading: Supply-Demand Imbalance

New Horizon Health (诺辉健康) IPO: Room to Fly

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>New Horizon Health released positive profit alert last Friday. We speak with management post the profit alert.</li>
<li>The company is expected to achieve 410.9% total revenue growth compared to a year ago in 1H2022, based on the middle point of guidance.</li>
<li>The company has also achieved margin expansion thanks to a favorable change of mix to the high margin channel. </li>
</ul>


New Horizon Health released positive profit alert last Friday. We speak with management post the profit alert.
The company is expected to achieve 410.9% total revenue growth compared to a year ago in 1H2022, based on the middle point of guidance.
The company has also achieved margin expansion thanks to a favorable change of mix to the high margin channel. 


New Horizon Health-B: Ups Full Year Guidance by 20% Despite Pandemic